Does Everolimus in Gastrointestinal, Lung NETs Delay Progression at Expense of Health-Related QOL?
Do you know the quality-of-life impact of everolimus in gastrointestinal or lung neuroendocrine tumors? Do you know the associations between neuroendocrine tumors and MEN1? Test your knowledge on these topics and more in our latest quiz.
Do you know the quality-of-life impact of everolimus in gastrointestinal or lung neuroendocrine tumors? Do you know the associations between neuroendocrine tumors and MEN1? Test your knowledge on these topics and more in our latest quiz on neuroendocrine tumors.
Question 1
Answer
B. False. In the randomized phase III RADIANT-4 trial, HRQOL was maintained for patients with advanced, non-functional, gastrointestinal or lung NETs, with no relevant differences noted between the everolimus and placebo groups.
Reference
Pavel ME, Singh S, Strosberg JR, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1411-22.
Question 2
Answer
B. Patients with familial hyperparathyroidism including MEN1 are less likely to develop recurrent disease compared to sporadic hyperparathyroidism. Patients with familial hyperparathyroidism including MEN1 are more likely, not less likely, to develop recurrent disease compared to sporadic hyperparathyroidism. So Answer B is the false statement.
Reference
Montenegro FL, Lourenço DM Jr, Tavares MR, et al. Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center. Clinics (Sao Paulo). 2012;67(suppl 1):131-9.
Question 3
Answer
A.MEN1 is associated with pituitary gland and parathyroid tumors, pancreatic NETs, but not carcinoid or adrenal tumors, lipomas, or skin angiomas. MEN1, or Wermer syndrome, is characterized by tumors of the parathyroid and pituitary glands and pancreatic NETs, but may also be associated with carcinoid tumors of thymus, bronchial, gastric, adrenal tumors, and multiple lipomas and skin angiomas. So Answer A is the false statement.
Reference
Marx S, Spiegel AM, Skarulis MC, et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998;129:484-94.
Question 4
Answer
D. D. Symptomatic functional tumors of any size. Symptomatic functional tumors of any size should not be removed unless they are refractory to medical treatment.
Reference
Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol. 2015;3:895-905.
Question 5
Answer
D. All of the above are true.
Reference
Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98:3149-64.
This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.
Oncology Peer Review On-The-Go: COVID-19, Cancer, and the Potential of mRNA Vaccines
March 30th 2021Mehmet Sitki Copur, MD, discussed his article in the Journal ONCOLOGY® focusing on COVID-19, messenger RNA vaccines, and the excitement surrounding its integration into the future of cancer treatment.
ABSTRACT: Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non–small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.
Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive
ABSTRACT Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract. They commonly present with nonspecific symptoms and thus are often discovered incidentally. They are best identified by CT scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. Several risk stratification classification systems have been developed based on tumor size, mitotic rate, location, and perforation. Traditional chemotherapy and radiation therapy have been very ineffective, making surgery the mainstay of treatment. The discovery of mutations associated with these tumors has revolutionized the treatment approach. Imatinib mesylate, a selective tyrosine kinase receptor inhibitor, used as adjuvant or neoadjuvant therapy, has greatly improved the morbidity and mortality associated with GISTs. As the survival of patients has increased with the long-term use of targeted therapies, quality-of-life issues now have become much more relevant and have come to the forefront of care. We present a young woman who was successfully treated for GIST but now faces associated long-term adverse effects of imatinib, including the challenge of preserving fertility and the potential for childbearing.
